公开(公告)号：EP3843722B1

公开(公告)日：2024-10-30

申请号：EP19853580.9

申请日：2019-08-27

发明人： CHO, Tae Keun ,  CHO, Young Dae ,  KWON, Eunji ,  SHIN, Myung Jin

IPC分类号： A61K31/4184 ,  A61K31/4365 ,  A61K9/00 ,  A61P1/04 ,  A61P7/02 ,  A61K9/16 ,  A61K9/20 ,  A61K9/24

公开(公告)号：EP4445897A2

公开(公告)日：2024-10-16

申请号：EP24192344.0

申请日：2020-04-17

申请人： Fertin Pharma A/S

发明人： NIELSEN, Bruno Provstgaard ,  BOESEN, Dorthe Schackinger ,  BRUUN, Heidi Ziegler ,  NIELSEN, Kent Albin ,  PRANGER-RASMUSSEN, Rikke

IPC分类号： A61K9/24

摘要： A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first and second modules being formed by a plurality of compressed particles, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine, wherein the second module comprises disintegrant.

公开(公告)号：EP3930473B1

公开(公告)日：2024-07-10

申请号：EP19805888.5

申请日：2019-10-10

IPC分类号： A61K9/68 ,  A61K9/20 ,  A61K31/05 ,  A23G4/06 ,  A23G4/12 ,  A23L33/105 ,  A61K9/24

CPC分类号： A23G4/12 ,  A23G4/06 ,  A23G4/068 ,  A23L33/105 ,  A61K9/0058 ,  A61K9/2095 ,  A61K9/2027 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/205 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2086 ,  A61K31/05

公开(公告)号：EP4368174A1

公开(公告)日：2024-05-15

申请号：EP22837869.1

申请日：2022-06-27

申请人： Hanmi Pharm. Co., Ltd.

发明人： TAK, Jin Wook ,  BAEK, Ji Won ,  KWON, Taek Kwan ,  IM, Ho Taek ,  KIM, Yong Il

IPC分类号： A61K9/24 ,  A61K9/20 ,  A61K31/4985 ,  A61K31/7034 ,  A61K31/155 ,  A61P3/10

CPC分类号： A61K9/209 ,  A61K31/4985 ,  A61P3/10 ,  A61K9/20 ,  A61K31/7034 ,  A61K31/155

摘要： The present invention relates to an oral complex table in the form of a bi-layer tablet, which contains colloidal silicon dioxide in an amount of 0.5 to 2% by weight based on the total weight of the first layer, and a method for manufacturing thereof.

公开(公告)号：EP3329921B1

公开(公告)日：2024-03-27

申请号：EP16830578.7

申请日：2016-07-28

发明人： MAEDA, Arisa ,  SUGIYAMA, Yuichi ,  UCHIYAMA, Yoshihiro

IPC分类号： A61K9/24 ,  A61K9/30 ,  A61K31/616 ,  A61K31/4439 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38 ,  A61P1/04 ,  A61P7/02 ,  A61P9/00 ,  A61P9/12 ,  A61P29/00 ,  A61K31/18

公开(公告)号：EP4321156A1

公开(公告)日：2024-02-14

申请号：EP22884061.7

申请日：2022-10-20

申请人： Han Wha Pharma Co., Ltd.

发明人： CHAE, Yu Byeong ,  SHIN, Seo Young ,  LIM, Chae Yong ,  OH, Dong Joon

IPC分类号： A61K9/24 ,  A61K9/20 ,  A61K47/20 ,  A61K47/12 ,  A61K9/28 ,  A61K31/47 ,  A61K31/495

摘要： Provided are a tablet comprising: a first drug layer comprising montelukast or a pharmaceutically acceptable salt thereof; a second drug layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; an inner layer being in contact with the first drug layer from one side and in contact with the second drug layer from the other side, such that the first drug layer and the second drug layer are non-contact; and an outer layer comprising the first drug layer, the inner layer, and the second drug layer, and a method for manufacturing the same.
The tablet of the present invention, in which montelukast and levocetirizine are present in a single tablet, but not contacted by a boundary layer, can be usefully used in the pharmaceutical field as a composite formulation that can be manufactured in an efficient process while minimizing drug interactions.

公开(公告)号：EP4312998A1

公开(公告)日：2024-02-07

申请号：EP22782385.3

申请日：2022-03-24

申请人： The Trustees of The University of Pennsylvania ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： LEE, Daeyeon ,  JO, Yun Kee ,  MAUCK, Robert, Leon ,  DODGE, George, R.

IPC分类号： A61K9/50 ,  A61K38/18 ,  A61P19/04 ,  A61K9/24

公开(公告)号：EP4309648A1

公开(公告)日：2024-01-24

申请号：EP22770551.4

申请日：2022-03-16

申请人： Shanghai Yonsun Biotechnology Co., Ltd.

发明人： GUO, Zhen ,  CHEN, Zuyou ,  CHEN, Lina ,  WANG, Tingting ,  YING, Shuhuan ,  XIE, Wenfeng

IPC分类号： A61K9/22 ,  A61K9/24 ,  A61K9/20 ,  A61K9/28 ,  A61K31/165 ,  A61P25/08 ,  A61P25/14 ,  A61P25/18 ,  A61P25/06 ,  A61P25/02

摘要： The present disclosure provides a lacosamide pharmaceutical composition as well as a preparation method and application thereof. According to the lacosamide pharmaceutical composition according to the present disclosure, lacosamide or a pharmaceutically acceptable salt thereof can be dissolved out at the same time, wherein the dissolution rate of the lacosamide pharmaceutical composition is not more than 40% within 1 hour, the dissolution rate of the lacosamide pharmaceutical composition is 20-70% within 6 hours, and the dissolution rate of the lacosamide pharmaceutical composition is not less than 65% within 24 hours. The lacosamide pharmaceutical composition prepared according to the present disclosure has good slow release performance, the tablet size can be rapidly expanded in the in-vitro dissolution process, the expanded lacosamide pharmaceutical composition has good rigidity and elasticity and has a remarkable retention effect in the stomach, and the cumulative release rate within 24 hours can reach 80% or above. According to the preparation process, the problems of difficulty in filling, unstable tablet weight and the like in the tabletting process caused by poor flowability and too low bulk density of the raw material medicines are obviously improved, the process is stable, the process parameters are adjustable and controllable, the production amplification of the product is facilitated, and the market prospect is good.

公开(公告)号：EP3634387B1

公开(公告)日：2024-01-17

申请号：EP18703465.7

申请日：2018-01-25

发明人： MCNALLY, Gerard, P. ,  ANDERSON, Oliver ,  KOLL, Gregory

IPC分类号： A61K9/24

公开(公告)号：EP4297733A1

公开(公告)日：2024-01-03

申请号：EP22707862.3

申请日：2022-02-23

申请人： Teva Pharmaceutical Industries Ltd.

发明人： THEURER, Marc ,  STEIGERWALD, Mario

IPC分类号： A61K9/20 ,  A61K9/24 ,  A61K9/48 ,  A61K31/138 ,  A61K31/4422 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/64 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12